|
1.
|
Szuhai K, Cleton-Jansen AM, Hogendoorn PC
and Bovée JV: Molecular pathology and its diagnostic use in bone
tumors. Cancer Genet. 205:193–204. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Kuchroo VK, Dardalhon V, Xiao S and
Anderson AC: New roles for TIM family members in immune regulation.
Nat Rev Immunol. 8:577–580. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kuchroo VK, Umetsu DT, DeKruyff RH and
Freeman GJ: The TIM gene family: emerging roles in immunity and
disease. Nat Rev Immunol. 3:454–462. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sonar SS, Hsu YM, Conrad ML, et al:
Antagonism of TIM-1 blocks the development of disease in a
humanized mouse model of allergic asthma. J Clin Invest.
120:2767–2781. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
5.
|
de Souza AJ, Oriss TB, O’malley KJ, Ray A
and Kane LP: T cell Ig and mucin 1 (TIM-1) is expressed on in
vivo-activated T cells and provides a costimulatory signal for T
cell activation. Proc Natl Acad Sci USA. 102:17113–17118.
2005.PubMed/NCBI
|
|
6.
|
Rodriguez-Manzanet R, Sanjuan MA, Wu HY,
et al: T and B cell hyperactivity and autoimmunity associated with
niche-specific defects in apoptotic body clearance in
TIM-4-deficient mice. Proc Natl Acad Sci USA. 107:8706–8711. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Monney L, Sabatos CA, Gaglia JL, et al:
Th1-specific cell surface protein Tim-3 regulates macrophage
activation and severity of an autoimmune disease. Nature.
415:536–541. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Sakuishi K, Apetoh L, Sullivan JM, Blazar
BR, Kuchroo VK and Anderson AC: Targeting Tim-3 and PD-1 pathways
to reverse T cell exhaustion and restore anti-tumor immunity. J Exp
Med. 207:2187–2194. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Freeman GJ, Casasnovas JM, Umetsu DT and
DeKruyff RH: TIM genes: a family of cell surface phosphatidylserine
receptors that regulate innate and adaptive immunity. Immunol Rev.
235:172–189. 2010.PubMed/NCBI
|
|
10.
|
Zhuang X, Zhang X, Xia X, et al: Ectopic
expression of TIM-3 in lung cancers: a potential independent
prognostic factor for patients with NSCLC. Am J Clin Pathol.
137:978–985. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Li H, Wu K, Tao K, et al: Tim-3/galectin-9
signaling pathway mediates T-cell dysfunction and predicts poor
prognosis in patients with hepatitis B virus-associated
hepatocellular carcinoma. Hepatology. 56:1342–1351. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Dorfman DM, Hornick JL, Shahsafaei A and
Freeman GJ: The phosphatidylserine receptors, T cell immunoglobulin
mucin proteins 3 and 4, are markers of histiocytic sarcoma and
other histiocytic and dendritic cell neoplasms. Hum Pathol.
41:1486–1494. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Yang ZZ, Grote DM, Ziesmer SC, et al:
IL-12 upregulates TIM-3 expression and induces T cell exhaustion in
patients with follicular B cell non-Hodgkin lymphoma. J Clin
Invest. 122:1271–1282. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Baghdadi M, Nagao H, Yoshiyama H, Akiba H,
Yagita H, Dosaka-Akita H and Jinushi M: Combined blockade of TIM-3
and TIM-4 augments cancer vaccine efficacy against established
melanomas. Cancer Immunol Immunother. 62:629–637. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Lim J and Thiery JP:
Epithelial-mesenchymal transitions: insights from development.
Development. 139:3471–3486. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Wu CY, Tsai YP, Wu MZ, Teng SC and Wu KJ:
Epigenetic reprogramming and post-transcriptional regulation during
the epithelial-mesenchymal transition. Trends Genet. 28:454–463.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Fernandez IE and Eickelberg O: The impact
of TGF-β on lung fibrosis: from targeting to biomarkers. Proc Am
Thorac Soc. 9:111–116. 2012.
|
|
18.
|
Hermeking H: MicroRNAs in the p53 network:
micromanagement of tumour suppression. Nat Rev Cancer. 12:613–626.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Gao D, Vahdat LT, Wong S, Chang JC and
Mittal V: Microenvironmental regulation of epithelial-mesenchymal
transitions in cancer. Cancer Res. 72:4883–4889. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Rangel MC, Karasawa H, Castro NP, Nagaoka
T, Salomon DS and Bianco C: Role of Cripto-1 during
epithelial-to-mesenchymal transition in development and cancer. Am
J Pathol. 180:2188–2200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Hamilton DH, Litzinger MT, Fernando RI,
Huang B and Palena C: Cancer vaccines targeting the
epithelial-mesenchymal transition: tissue distribution of brachyury
and other drivers of the mesenchymal-like phenotype of carcinomas.
Semin Oncol. 39:358–366. 2012. View Article : Google Scholar
|
|
22.
|
Li H, Wang C, Guo G, Gao C, Wu Y and Chen
Y: The characteristic expression of B7-associated proteins in
Langerhans cell sarcoma. Acta Histochem. 114:733–743. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Guo Y, Zi X, Koontz Z, Kim A, Xie J,
Gorlick R, Holcombe RF and Hoang BH: Blocking Wnt/LRP5 signaling by
a soluble receptor modulates the epithelial to mesenchymal
transition and suppresses met and metalloproteinases in
osteosarcoma Saos-2 cells. J Orthop Res. 25:964–971. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Niinaka Y, Harada K, Fujimuro M, et al:
Silencing of autocrine motility factor induces
mesenchymal-to-epithelial transition and suppression of
osteosarcoma pulmonary metastasis. Cancer Res. 70:9483–9493. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Sarsilmaz A, Argin M, Sezak M, Altay C and
Erdogan N: Primary osteosarcoma arising from subcutaneous tissue:
5-year follow-up. Clin Imaging. 36:402–405. 2012.PubMed/NCBI
|
|
26.
|
Eyre R, Feltbower RG, James PW, Blakey K,
Mubwandarikwa E, Forman D, McKinney PA, Pearce MS and McNally RJ:
The epidemiology of bone cancer in 0–39 year olds in northern
England, 1981–2002. BMC Cancer. 10:3572010.
|
|
27.
|
Andrews EB, Gilsenan AW, Midkiff K,
Sherrill B, Wu Y, Mann BH and Masica D: The US postmarketing
surveillance study of adult osteosarcoma and teriparatide: Study
design and findings from the first 7 years. J Bone Miner Res.
27:2429–2437. 2012.
|
|
28.
|
Mavrogenis AF, Rossi G, Palmerini E, et
al: Palliative treatments for advanced osteosarcoma. J BUON.
17:436–445. 2012.
|
|
29.
|
McConkey DJ, Choi W, Marquis L, et al:
Role of epithelial-to-mesenchymal transition (EMT) in drug
sensitivity and metastasis in bladder cancer. Cancer Metastasis
Rev. 28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Dunning NL, Laversin SA, Miles AK and Rees
RC: Immunotherapy of prostate cancer: should we be targeting stem
cells and EMT? Cancer Immunol Immunother. 60:1181–1193. 2011.
View Article : Google Scholar : PubMed/NCBI
|
